Discontinuation report TASIGNA
| Report ID | 207564 |
| Drug Identification Number | 02481715 |
| Brand name | TASIGNA |
| Common or Proper name | TASIGNA 50 MG 3(5X8) |
| Company Name | NOVARTIS PHARMACEUTICALS CANADA INC |
| Market Status | CANCELLED POST MARKET |
| Active Ingredient(s) | NILOTINIB |
| Strength(s) | 50MG |
| Dosage form(s) | CAPSULE |
| Route of administration | ORAL ORAL |
| Packaging size | 3(5 X 8) |
| ATC code | L01EA |
| ATC description | |
| Reason for discontinuation | Business reasons |
| Anticipated discontinuation date | 2023-10-24 |
| Actual discontinuation date | 2023-10-24 |
| Remaining supply date | 2025-10-31 |
| Discontinuation status | Discontinued |
| Discontinuation decision reversal | No |
| Information on remaining supply | |
| Company comments | |
| Health Canada comments | |
| Tier 3 Status | No |
| Contact Address | 700 RUE SAINT-HUBERT MONTREAL, QUEBEC CANADA H2Y 0C1 |
| Company contact information | customer.relations@novartis.com |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
| Version Number | Date Updated | Language | |
|---|---|---|---|
| v5 | 2023-11-06 | French | Compare |
| v4 | 2023-11-06 | English | Compare |
| v3 | 2023-10-19 | French | Compare |
| v2 | 2023-10-19 | English | Compare |
| v1 | 2023-10-19 | English | Compare |
Showing 1 to 5 of 5